Conferences - Results from #380

Viewing 381-400 of 11869 articles

BCANTT 2024: Disrupting the Paradigm of First-line Therapy in Metastatic Urothelial Cancer

BCANTT 2024: Identifying Individual and Community-Level Drivers of Disparities in Bladder Cancer Clinical Trials Participation

AMA 2024: Updates on Public Health Related Policy Adopted at the AMA 2024 Annual Meeting

SNMMI 2024: Response Assessment in RPTs for Prostate Cancer: Everyone’s A Winner

AMA 2024: Updates on Legislation Related Policy Adopted at the AMA 2024 Annual Meeting

AMA 2024: Updates on Science and Technology Related Policy Adopted at the AMA 2024 Annual Meeting

AMA 2024: Updates on Medical Practice Related Policy Adopted at the AMA 2024 Annual Meeting

ASCO 2024: Validation of a Digital Pathology-Based Multimodal Artificial Intelligence Model in Oligometastatic Castration-Sensitive Prostate Cancer, Including in Patients from the STOMP and ORIOLE Phase II Randomized Clinical Trials

SNMMI 2024: Registrational Trials for PSMA PET

SNMMI 2024: Prognostic Value of Post-Therapy SPECT/CT Imaging in Patients Undergoing 177Lu-PSMA-617 Radioligand Therapy: Results from 3 Clinical Trials

SNMMI 2024: PSMA PET/CT Radiomics: Assessment of Adverse Pathological Risk and Proteomic Biomarker Correlations in Prostate Cancer

SNMMI 2024: Development of a Visually Calculated SUVmean (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to 177Lu PSMA Therapy: Comparison to Quantitative SUVmean and Patient Outcomes

SNMMI 2024: 18F-DCFPyL PET/MRI Radiomics for Intraprostatic Prostate Cancer Detection and Metastases Prediction Using Whole-Gland Segmentation

SNMMI 2024: Comparison of Post-Therapy 4 and 24-hour 177Lu-PSMA SPECT/CT and Pre-Therapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castrate-Resistant Prostate Cancer

SNMMI 2024: 68Ga-P16-093 Diagnostic Performance in Newly Diagnosed Prostate Cancer- Histopathologic Correlation

SNMMI 2024: Determining the Simplified Quantification Method of [18FAlF-P16-093 for Patients with Primary Prostate Cancer

SNMMI 2024: Eligibility for PSMA-RLT Based on Dual FDG/PSMA-PET: A Subanalysis of the 3TMPO Study

SNMMI 2024: COBRA: Assessment of Safety and Efficacy of 64Cu-SAR-bisPSMA in Patients with Biochemical Recurrence of Prostate Cancer Following Definitive Therapy

SNMMI 2024: Non-PSMA Targets for Prostate Cancer Radiopharmaceutical Therapies

SNMMI 2024: VIOLET: Radiation Absorbed Dose in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with 161Tb-PSMA-I&T

15
16
17
18
19
20
21
22
23
24